SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as the community celebrates the FDA approval of YARTEMLEA, the first and only therapy for transplant-associated thrombotic microangiopathy in adults and children, sparking immense optimism among long-term investors. Many are eagerly discussing the potential for a significant re-rating of the company's valuation and a substantial short squeeze. This milestone, coupled with a multi-billion dollar partnership, has led to widespread belief that the company is now de-risked and poised for considerable growth.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA CRYPTO) is trending due to its high-speed, compliance-first Layer 1 infrastructure, which boasts impressive transaction throughput. The community is actively discussing its potential as a "financial plumbing" solution for institutions, especially with its integration of a fiat anchor from Bridge (a Stripe company) now operational. Many view KTA as an undervalued asset for cross-chain settlement and regulated financial flows, positioning it as a compelling complementary play to established crypto and tech giants.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is experiencing significant upward momentum, driven by positive regulatory developments, strategic divestitures, and key partnerships in wealth management and digital payments. This rally has sparked extensive community discussion, with many celebrating its strong performance and ongoing transformation plan, while others express caution due to its rapid ascent and overbought technical indicators. The positive sentiment is reinforced by strong earnings and analyst upgrades, positioning it as a notable performer within the broader financial sector.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending following a definitive agreement for acquisition by Sanofi for a notable cash value, which sent the stock surging. The community is actively discussing the offer, with many long-term shareholders expressing mixed sentiments: celebrating significant gains while a vocal segment believes the valuation is too low given the company's Hepatitis B vaccine, Heplisav-B, and promising shingles vaccine candidate.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

The Metals Company (TMC) is gaining significant attention following the U.S. government's NOAA formally advancing its deep seabed mining exploration license applications, confirming full compliance. This development is widely seen by the community as a major de-risking event and a clear signal of U.S. commitment to securing critical mineral supply, fueling strong bullish sentiment and anticipation of accelerated regulatory progress for this emerging industry.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful orbital launch of its BlueBird 6 satellite, the largest commercial communications array ever deployed, designed to bring 4G and 5G directly to standard smartphones. This major milestone has generated widespread excitement, though the community is actively discussing a "sell the news" dynamic leading to profit-taking. However, many long-term investors are accumulating on dips, anticipating future satellite deployments and substantial revenue potential as the company progresses towards global connectivity.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is sparking heated discussions, with some community members alleging it's a "scam" or "rugpull" while others see it as deeply oversold and poised for a bounce. Amidst this, the ecosystem's advancements, including the launch of Midnight and the perceived complementary role of high-performance infrastructure like Keeta with its Stripe integration, are driving conversation around its future in compliant financial systems.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending after receiving FDA approval for Aqvesme, its treatment for anemia in adults with alpha- or beta-thalassemia, making it the only medicine approved for both forms of the rare blood disorder. While this marks a significant market opportunity, community discussion is weighing this breakthrough against the required risk management program and the treatment's anticipated availability, alongside lingering sentiment from previous mixed clinical trial outcomes for a separate indication.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending after promising preliminary Phase 3 data for its breast cancer immunotherapy showed an estimated 80% reduction in recurrence rates, driving intense bullish sentiment. The community is actively discussing perceived undervaluation, continued insider buying by the CEO, and the escalating potential for a significant short squeeze, fueled by exceptionally high borrow rates and a tightly held float.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is trending as substantial insider buying, coupled with a public offering, conveys management's confidence despite a regulatory complete response letter for one of its lead programs. Community discussion is further energized by encouraging early clinical data for its experimental cancer treatment, BHV-1510, which demonstrated notable response rates and a favorable safety profile. Investors are now closely watching for upcoming readouts from its major depressive disorder and epilepsy programs for additional catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of "Moderate Buy" by Analysts

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering...

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells $500,714.88 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 12,048 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold...

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Barry Quart Sells 20,129 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) Director Barry Quart sold 20,129 shares of the business's stock in a transaction that occurred on Monday, December 15th. The...

Braidwell LP Sells 860,329 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Braidwell LP lessened its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 43.8% during the second quarter, according to the company in its most recent...

Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CFO Sells 42,841 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 42,841 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold...

Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Walleye Capital LLC

Walleye Capital LLC increased its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 39.1% in the 2nd quarter, according to its most recent 13F filing with the SEC...

Wedbush Reiterates Outperform Rating for Kiniksa Pharmaceuticals International (NASDAQ:KNSA)

Wedbush reissued an "outperform" rating and issued a $48.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Tuesday...

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are covering the...

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 12-Month High - Time to Buy?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High - Time to Buy...

200,574 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Purchased by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. bought a new position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the second quarter, according to its most recent 13F filing...

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

KNSA
Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KNSA News

KNSAKiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A